DailyIQ
|
Sector:HealthcareAll sectors
Last updatedUpdating…

JNJ·Johnson & Johnson

$253.94
+5.33 (+2.14%)
After Hours
High
$253.94
Open
$249.09
Market Cap
601.22B
52W High
$281.07
Low
$248.50
P. Close
$253.94
P/E
28.58
52W Low
$184.66
Fwd P/E
20.88
DailyIQ Est.
$289.42
Inst. Ownership
36.5%
Short Interest
0.92%
Days to Cover
3.3
Div. Yield
2.12%
Next Ex-Div
~Nov 24
Div. Growth
55+ yrs
NewEarnings release, scored · filed Oct 13, 2026Guidance raised · tone -2.7 vs prior release · 33 lines scoredSee the breakdown
Technical Score (1D)
83
BULLISH
News Sentiment
49
MIXED
On Oct 14, Johnson & Johnson announced its intent to pursue strategic acquisitions to reach more than $50 billion in oncology sales by 2030, a move that reinforced the company’s commitment to expanding its cancer‑drug portfolio and signaled potential deal activity. The same day, investors increased positions in Sellas Life Sciences and ImmunityBio, underscoring the focus on oncology growth. On Oct 13, the company’s Q3 2026 earnings call highlighted a $7 billion talc litigation settlement that drove net earnings to $210 million and a $1 billion Firefly Bio acquisition expense that added to R&D costs, leading to a decline in enterprise margin from 35.2% to 30.2%. That quarter also saw revenue rise 6% to $25.4 billion, largely driven by a 7.9% increase in its Innovative Medicine segment, while adjusted earnings per share fell 7.5% to $2.59 due to acquisition dilution and a $7 billion special charge. On Oct 13, the company raised its 2026 adjusted earnings guidance to $11.10 per share, yet shares fell 4.7% as investors expressed concerns that the higher forecast may not translate into stronger earnings growth, particularly in the MedTech segment. The same day, a 6% decline in the stock followed a miss in MedTech sales estimates, reflecting worries about the future of the company’s medical device business and its impact on valuation.
LOW TARGET
$190 -25.2%
2 analysts
MEAN TARGET
$279 +9.8%
19 analysts
HIGH TARGET
$320 +26.0%
12 analysts
PRICE RANGE
$190.00 - $320.00
SB / B / H / S / SS
7/15/9/1/1
DAILYIQ EST.
$289.42 (+14.0%)
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYQ
Country
United States
Website
jnj.com
Symbol
JNJ
Description
Johnson & Johnson is a global healthcare giant focused on two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division develops and markets prescription drugs targeting a broad range of therapeutic areas, including immunology, oncology, neuroscience, and cardiovascular diseases, reaching patients through various distribution channels. The MedTech segment provides a diverse portfolio of medical devices and technologies, such as those used in electrophysiology, orthopedics, surgery, and vision care, including contact lenses and intraocular lenses. This segment serves hospitals, retailers, and healthcare professionals. Founded in 1886, Johnson & Johnson leverages its extensive research and development capabilities to deliver innovative healthcare solutions worldwide, solidifying its position as a diversified leader in the industry.
Bought (1Y)
0 shares
$0
Sold (1Y)
269,340 shares
$70.2M
HEWSON MARILLYN A-
Award/Grant180.956 shares2026-09-08
Woods Eugene A.-
Award/Grant135.717 shares2026-09-08
Pinto Daniel E-
Award/Grant113.098 shares2026-09-08
Schmid TimothyEVP, WW Chair, MedTech
Option Exercise22,527 shares2026-09-02
Schmid TimothyEVP, WW Chair, MedTech
Option Exercise11,070 shares2026-09-02
View full insider trading history →
75/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
67.9%
Net Margin
28.5%
Revenue CAGR
2.9%
Current Ratio
1.03x
Debt / Equity
0.56x
Return on Equity
36.2%
View full financials →
Earnings Summary
Johnson & Johnson is a diversified global healthcare company with core segments in Innovative Medicine and MedTech, delivering prescription drugs across immunology, oncology, and cardiovascular areas, and a broad medical device portfolio, anchoring it within the drug manufacturers industry. In the latest quarter, Q4 2025, JNJ posted EPS of $2.46 versus an estimate of $2.46, essentially meeting expectations, while revenue reached $24.56 billion against an estimate of $24.40 billion, a modest 0.6% increase from Q3 2025’s $23.99 billion; EPS growth slowed slightly from $2.80 in Q3 2025 to $2.46 in Q4 2025, indicating a deceleration in earnings momentum. Over the past eight quarters, JNJ has shown a steady YoY revenue growth trajectory, with EPS generally beating or meeting estimates, though the most recent quarter saw a slight EPS miss relative to the prior period, reflecting a consistent pattern of strong revenue but occasional earnings volatility. Recent news on October 11, 2026 underscored JNJ’s focus on its Innovative Medicine pipeline, including the FDA approval of its IL‑23 inhibitor TREMFYA for Crohn’s disease, and highlighted the company’s 64th consecutive dividend increase, reinforcing its dividend king status; these developments support the company’s earnings stability and investor appeal.

EPS

EstBeatMiss
$2.39$2.54$2.68$2.82$2.97Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.59$2.59+0.1%
Q2'26$2.87$2.90+0.9%
Q1'26$2.88$2.70-6.4%
Q4'25$2.46$2.46-0.1%
Q3'25$2.76$2.80+1.5%

Revenue

EstBeatMiss
$23.8B$24.3B$24.8B$25.3B$25.8BQ3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$25.6B$25.4B-0.7%
Q2'26$25.3B$25.3B+0.0%
Q1'26$25.0B$24.1B-3.9%
Q4'25$24.4B$24.6B+0.7%
Q3'25 - $24.0B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

JNJ Stock Snapshot

BULLISH83/100
$253.89−$0.05 (0.0%)
Market cap
601.22B
P/E ratio
28.6
Day range
$248.50 – $253.94
News sentiment
49/100 · Neutral
Analyst target
$278.68 (+9.8%)
Consensus
Buy · 33 analysts
52-week range+37.5% off low · -9.7% from high
$184.66$281.07
Price $253.89 DailyIQ Est. $289.42

Price is in the upper part of its 52-week range, and the momentum read backs that positioning up. Coverage is deep enough that new information gets priced quickly, so surprises tend to be macro rather than fundamental.

Reverse DCF

What growth is priced into JNJ?

RICH

At today's price, Johnson & Johnson needs to grow free cash flow about 9.1% a year for the next 10 years to justify its valuation at a 6.80% cost of capital. Over its actual history it has compounded free cash flow at 3.9% a year, so the market is asking for 5.2 percentage points above its own delivered rate. On that basis JNJ looks priced above what its own growth record supports.

Implied FCF growth
9.1%
Historical FCF CAGR
3.9%
Growth gap
+5.2 pts
Verdict
RICH
Discount rate (WACC)
6.80%
Beta
0.37

Behaviour On Record

What JNJ's own history says about today's numbers

Realized volatility (21d)
26.1% 94th pct
Below its peak
-9.8%
vs 200-day average
+2.9%
Up days (1y)
52%

Johnson & Johnson is currently running 26.1% annualised volatility over the last 21 sessions. Measured against JNJ's own 13 years of daily returns rather than a market-wide average, that is the 94th percentile — an extreme by its own standards, against a typical reading of 14.8%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

JNJ is trading -9.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -13.5%, and the deepest was -26.0% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +2.9% from its 200-day moving average. Against every other day in its history, that gap ranks at the 52nd percentile — close to the gap it normally carries. Over the past year JNJ closed higher on 52% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 14 years of records, JNJ finished the month higher 9 of 14 times, with a median return of +1.3% and an average of +1.0%. Its strongest month historically has been June at +2.3% on average, its weakest May at -0.8%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: JNJ has opened more than 2% away from the prior close in 16 of 3,268 sessions (0.5% of the time), with the largest gaps running +3.3% and -4.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 4 dated reports on file, JNJ moved an average of 0.9% in the session after earnings, closing higher 3 of those 4 times, with a median move of +0.5% and a largest of +1.5%.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against JNJ's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of JNJ's sector?

Johnson & Johnson sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82

Options Market

What is the options market pricing for JNJ?

CallsPuts

For Johnson & Johnson's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.84), with at-the-money implied volatility around 28.3%. The options market is pricing roughly a ±2.9% move by that expiry — a range of about $256.87–$272.13.

Put/call ratio (2026-10-16)
0.84
ATM implied volatility
28.3%
Total open interest
74,585
Expected move by 2026-10-16
±2.9% ($256.87–$272.13)

Analyst Rating Changes

Are analysts turning bullish or bearish on JNJ?

Wells Fargo most recently reiterated its rating on Johnson & Johnson to Overweight on Oct 14, 2026 with a price target of $275 (from $282). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Wells Fargo — Overweight
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 14, 2026Wells FargoMaintainedOverweight$282 → $275
Oct 14, 2026RBC CapitalMaintainedOutperform$290 → $280
Oct 7, 2026GuggenheimReiteratedBuy$287
Oct 6, 2026RBC CapitalMaintainedOutperform$287 → $290
Oct 5, 2026CitigroupMaintainedBuy$298 → $303
Sep 29, 2026JP MorganMaintainedNeutral$270 → $285
Sep 10, 2026HSBCMaintainedBuy$290 → $320
Sep 2, 2026UBSMaintainedBuy$280 → $320
Aug 6, 2026GuggenheimMaintainedBuy$270 → $287
Aug 3, 2026Wells FargoMaintainedOverweight$272 → $282
Jul 17, 2026GuggenheimReiteratedBuy$270
Jul 16, 2026Raymond JamesMaintainedOutperform$258 → $265

Earnings Release, Scored

What did Johnson & Johnson's latest earnings release say?

Filed Oct 13, 2026 · SEC Form 8-K, Exhibit 99

Guidance raised
Tone72.8/ 100-2.7 vs prior release
Hedging words0.40per 100 words+0.08 vs prior release
Tone, last 2 releasesScale 50–81

Most important lines

  1. 1

    Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.2 Billion or 7.4% at the midpoint and increasing adjusted EPS* guidance by $0.06 to $11.10 or 2.9% at the midpoint

    Guidance raised
  2. 2

    FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patientsPress Release

    New this quarter
  3. 3

    Growth was partially offset by STELARA (an approximate 690 basis points impact), SIMPONI/SIMPONI ARIA, and REMICADE in Immunology, as well as OPSUMIT/OPSYNVI in Pulmonary Hypertension, and IMBRUVICA in Oncology.

Scores describe the release's wording. They are not a forecast.

Read all 33 scored lines →

Peers & ETF holders

JNJ peers & ETF holders

Drug Manufacturers - GeneralMarket cap · today

Top ETF holdersWeight

News Sentiment Analysis

Sentiment gathered from recent headlines

49/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Johnson & Johnson announced its intent to pursue strategic acquisitions to reach more than $50 billion in oncology sales by 2030. The company’s focus on expanding its cancer‑drug portfolio was highlighted by recent ownership disclosures in Sellas Life Sciences and ImmunityBio, where several investors increased stakes. The announcement reinforced J&J’s commitment to growth in the oncology sector and signaled potential deal activity.
What did this article say?
The October 13 selloff of J&J shares underscored the impact of a broader medtech downturn, which outweighed the company's pharmaceutical business performance. Analysts noted that the decline in medtech earnings and guidance contributed to the negative market reaction. The event suggested that investors were re-evaluating the balance between J&J's drug and device segments, potentially affecting future valuation. This shift may prompt the company to reassess its strategic focus on high-growth medical technologies.
What did this article say?
Johnson & Johnson reported Q3 2026 results with worldwide sales of $25.4 billion, up 6% operationally. Net earnings fell sharply to $210 million, largely due to a $7 billion talc litigation settlement and $1 billion Firefly Bio acquisition expense. Adjusted earnings per share dropped 6.8% to $2.59, reflecting higher intangible amortization and other one‑time costs. The company’s enterprise margin declined from 35.2% to 30.2%, underscoring the impact of the legal and acquisition outlays. These losses represent a confirmed, material hit to JNJ’s profitability for the quarter.
What did this article say?
Johnson & Johnson reported Q3 2026 revenue of $25.4 billion, up 6.0% year‑over‑year, driven largely by a 7.9% increase in its Innovative Medicine segment. Adjusted earnings per share fell 7.5% to $2.59, largely due to dilution from the Firefly Bio acquisition and a Cell BioMedicines collaboration. GAAP EPS was $0.09, impacted by a $7 billion special charge related to talc litigation and ongoing strategic M&A activity.
What did this article say?
Johnson & Johnson increased its 2026 adjusted earnings guidance to $11.10 per share, yet the stock fell 4.7% on October 13. Quarterly sales reached $25.40 billion while adjusted earnings slipped 7.5% to $2.59 per share, partly due to a talc‑resolution charge and transaction items. Innovative Medicine revenue grew 7.7%, but MedTech revenue rose only 2.5%, leaving profit conversion weaker than expected. The market’s reaction reflected concerns that the higher forecast may not translate into stronger earnings growth, especially in the device segment.
What did this article say?
Johnson & Johnson experienced a 6% decline in its stock price following a miss in sales estimates for its MedTech division. The drop reflected investor concerns over the future of the company’s medical device segment, despite a broader earnings beat from the healthcare sector. The decline underscored the sensitivity of JNJ’s valuation to performance in its MedTech business and highlighted potential headwinds for the company’s growth trajectory.
What did this article say?
Johnson & Johnson announced its third‑quarter earnings were scheduled for release on Tuesday. Analysts projected modest revenue growth but anticipated lower earnings compared to prior periods. The guidance suggested a slight decline in profitability, reflecting broader market pressures on the healthcare sector. The company’s performance was highlighted amid a busy week of biotech updates and FDA decision timelines. The outlook indicated a cautious stance for investors assessing JNJ’s near‑term financial trajectory.
What did this article say?
Johnson & Johnson (JNJ) announced it would report third‑quarter results on October 13, ahead of the market open. Analysts projected a modest EPS increase to $2.82, with the company having consistently beat estimates in the past four quarters. The announcement highlighted JNJ’s focus on its Innovative Medicine and MedTech segments following the 2023 spin‑off of Kenvue.
What did this article say?
Johnson & Johnson’s shares rose 41% year‑to‑date, driven by investor confidence in its expanding product pipeline. The company’s IL‑23 inhibitor TREMFYA received FDA approval for Crohn’s disease in March 2025, adding to its ulcerative colitis indication. Analysts view the broadened pipeline, especially in oncology, immunology, and neuroscience, as a mild positive catalyst, though the upside is already largely reflected in the stock price.
What did this article say?
Johnson & Johnson’s dividend yield of 3.12% and an 8‑out‑of‑10 rating underscored its robust profitability and moderate health sector support, reinforcing the company’s reputation for a durable payout. The analysis highlighted the firm’s capacity to sustain dividend payments, appealing to income‑focused investors.

Technical Analysis

Real-time indicators across multiple timeframes

83
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $209.31B combined position · 13 adding, 12 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▼ Sell212,098,2648.84%$53.87B2026-08-07
Vanguard Group Inc▲ Buy240,349,66010.02%$49.74B2026-01-29
JPMorgan Chase & Co▼ Sell58,301,6092.43%$15.07B2026-08-12
Geode Capital Management, LLC▼ Sell59,086,4172.46%$14.97B2026-08-12
Morgan Stanley▲ Buy44,808,2541.87%$11.38B2026-08-13
Norges Bank▼ Sell31,825,0841.33%$8.08B2026-08-12
Northern Trust Corp▼ Sell28,792,0641.20%$7.31B2026-08-13
Bank of America Corp▼ Sell23,438,1410.98%$5.95B2026-08-14
FMR LLC (Fidelity)▼ Sell22,595,5660.94%$5.74B2026-08-13
Wellington Management Group LLP▲ Buy22,588,6960.94%$5.74B2026-08-14
Goldman Sachs Group Inc▲ Buy19,722,5440.82%$5.01B2026-08-14
Wells Fargo & Company▲ Buy17,374,4330.72%$4.41B2026-08-14
Invesco Ltd.▲ Buy15,674,0930.65%$3.98B2026-08-14
Capital World Investors▲ Buy15,215,0150.63%$3.86B2026-08-12
Fisher Asset Management, LLC▲ Buy13,307,0560.55%$3.38B2026-08-04
Capital Research Global Investors▼ Sell8,164,5450.34%$2.07B2026-08-12
Janus Henderson Group plc▲ Buy7,872,4780.33%$1.92B2026-05-18
AllianceBernstein L.P.▼ Sell6,867,2650.29%$1.68B2026-08-14
Neuberger Berman Group LLC▲ Buy4,126,1130.17%$1.05B2026-08-13
Citigroup Inc▲ Buy3,925,1860.16%$996.88M2026-08-03
Marshall Wace, LLP▲ Buy2,989,5370.12%$759.25M2026-08-13
AQR Capital Management LLC▼ Sell2,907,8030.12%$738.49M2026-08-14
Adage Capital Partners GP, L.L.C.▲ Buy2,566,5950.11%$651.84M2026-08-14
Prudential Financial Inc▼ Sell2,205,0620.09%$560.02M2026-08-12
Citadel Advisors LLC▼ Sell1,500,8320.06%$381.17M2026-09-02
Q2 2026 flow:15.14M sh bought ($3.85B)14.72M sh sold ($3.76B)net +426.5K sh (+$87.46M)
View full institutional holdings history →
Congressional Trading Activity
25 disclosed trades · ~$273.5K est. traded value · 8 buys, 17 sells
MemberChamberStateTypeAmountTradedFiled
Lloyd DoggettHouseTX37▲ Buy$1K - $15K2026-09-082026-10-05
Thomas H. KeanHouseNJ07▼ Sell$1K - $15K2026-08-272026-09-12
John BoozmanSenateAR▼ Sell$1K - $15K2026-08-202026-09-11
Richard Dean Dr McCormickHouseGA06▼ Sell$1K - $15K2026-07-302026-08-14
Thomas H. KeanHouseNJ07▼ Sell$1K - $15K2026-06-292026-07-15
Lloyd DoggettHouseTX37▲ Buy$1K - $15K2026-06-092026-07-06
Thomas H. KeanHouseNJ07▼ Sell$1K - $15K2026-06-022026-07-15
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-302026-07-21
Alan ArmstrongSenateOK▲ Buy$15K - $50K2026-03-272026-07-21
Thomas H. KeanHouseNJ07▼ Sell$1K - $15K2026-03-262026-04-13
Richard Dean Dr McCormickHouseGA06▼ Sell$1K - $15K2026-03-192026-04-07
John BoozmanSenateAR▼ Sell$1K - $15K2026-03-192026-04-14
Lloyd DoggettHouseTX37▲ Buy$1K - $15K2026-03-102026-04-06
Thomas H. KeanHouseNJ07▼ Sell$15K - $50K2026-01-232026-02-19
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-12-182026-01-15
Lloyd DoggettHouseTX37▲ Buy$1K - $15K2025-12-092026-01-02
Thomas H. KeanHouseNJ07▼ Sell$15K - $50K2025-11-202025-12-19
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-11-132025-12-11
Richard Dean Dr McCormickHouseGA06▲ Buy$1K - $15K2025-11-052025-12-09
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-312025-11-21
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-10-302025-11-21
Jared MoskowitzHouseFL23▼ Sell$1K - $15K2025-10-102025-11-22
Valerie HoyleHouseOR04▼ Sell$1K - $15K2025-09-232025-10-10
Kelly Louise MorrisonHouseMN03▼ Sell$1K - $15K2025-08-192025-09-11
View full congressional trading history →

Discover More

VTRS
Viatris Inc.
$17.44
-0.11%
VEA
Vanguard FTSE Developed Markets ETF
$69.20
-0.16%
WAT
Waters Corporation
$435.00
-0.38%
STE
STERIS plc
$217.26
+0.00%
BSX
Boston Scientific Corporation
$42.95
-0.14%
COO
The Cooper Companies, Inc.
$54.88
+0.00%
PFE
Pfizer Inc.
$29.14
-0.31%
EXEL
Exelixis Inc.
$60.99
-0.03%
XPH
SPDR S&P Pharmaceuticals ETF
$62.07
-0.10%
MDGL
Madrigal Pharmaceuticals Inc.
$460.01
+0.06%